---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000092"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:04:29.335067+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# AEON Biopharma Q3 2024: FDA aligned on biosimilar path for ABP-450, but capital constraints persist

## Summary
- Held Biosimilar Initial Advisory meeting with FDA in Q3; aligned on 351(k) pathway using BOTOX as reference.
- Primary comparative analytical studies planned for Q4 2024, subject to securing capital resources.
- BPD Type 2 meeting with FDA targeted in 2025 to discuss study outcomes.
- CEO cites capital resources as single biggest limitation; evaluating all options to fund regulatory strategy.

## SEC filing metadata
- accession: 0001837607-24-000092
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000092/0001837607-24-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000092/aeon-20241113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000092
- JSON: https://secwatch.observer/filing/0001837607-24-000092.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.